The Inspire upper airway stimulation system consists of a small impulse generator implanted beneath the clavicle, a tunneled breathing sensing lead placed between the external and intercostal muscles, and a tunneled stimulation lead attached to the branch of the hypoglossal nerve that produces tongue protrusion. Image reprinted with permission from Inspire Medical Systems. To read this article on click here.The Inspire upper airway stimulation system includes a generator, sensing lead and stimulation lead. (ISRG) : Free Stock Analysis ReportĮdwards Lifesciences Corporation (EW) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%. Merit Medical has a long-term estimated growth rate of 11%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. Merit Medical reported first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed twice, the average being 1.9%. Intuitive Surgical has a long-term estimated growth rate of 13%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%. Intuitive Surgical reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average being 1.2%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%.Įdwards Lifesciences has a long-term estimated growth rate of 6.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Įdwards Lifesciences reported first-quarter 2023 adjusted earnings per share (EPS) of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Inspire Medical currently carries a Zacks Rank #2 (Buy).Ī few other top-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation EW, Intuitive Surgical, Inc. Rising operating costs weighed on the gross margin and resulted in its contraction. However, dismal bottom-line results were disappointing. In the same month, INSP announced its receipt of countrywide reimbursement approval in Belgium, effective immediately, at rates consistent with other countries around the world. In March, Inspire Medical received the FDA’s approval to offer Inspire therapy to pediatric patients with Down syndrome. sales territories in each quarter of 2023 also raise our optimism about the stock. Management’s expectations of activating more U.S. sales territories in the reported quarter look encouraging. Strength in year-over-year geographic results was promising.Īctivation of new U.S. The robust improvement of the top line was impressive. Inspire Medical exited the first quarter of 2023 with better-than-expected results. sales territories in each quarter of 2023. medical centers providing Inspire therapy and add 12-14 new U.S. The Zacks Consensus Estimate for revenues is pegged at $570.1 million. The company projects revenues of $580-$590 million (suggesting growth of 42-45% from the 2022 reported levels), up from the earlier projection of $560-$570 million (indicating growth of 37-40% from the 2022 reported levels). Inspire Medical has revised its financial outlook for 2023. Revenues from outside the United States totaled $3.4 million, up 15% year over year on a reported basis. sales territories in the quarter, bringing the total to 242 U.S. medical centers providing Inspire therapy. centers, thus bringing the total to 973 U.S. In the reported quarter, Inspire Medical activated 68 new U.S. Per management, the upside can be attributed to several factors, including higher utilization at existing centers, addition of implanting centers, expanded direct-to-consumer marketing and a higher number of territory managers. revenues of $124.5 million reflected an increase of 87% from the year-ago quarter on a reported basis. Inspire Medical’s operations consist of two geographic regions - the United States and All other countries.įor the quarter under review, U.S. revenues and revenues outside the United States (All other countries). The top line benefited from strength in U.S. Activation of new centers also complimented the improvement. Per management, top-line growth was driven by higher utilization at existing centers. The figure surpassed the Zacks Consensus Estimate by 6.1%. Inspire Medical registered revenues of $127.9 million in the first quarter, up 84.3% year over year. The metric was narrower than the Zacks Consensus Estimate of a loss of 70 cents. INSP delivered a loss of 53 cents per share in first-quarter 2023 compared with the year-ago loss of 61 cents.
0 Comments
Leave a Reply. |